MEFs p53
-/-cells, and whole cell lysates immunoblotted. R132C decreases mTOR activity. IDH1 R132C/WT heterozygous HT1080 cells were treated for 3 days with 7.5 µM AGI-5198, a specific inhibitor of mutated IDH1. (g) AGI-5198-mediated inhibition of IDH1 R132C decreases 2HG intracellular levels. HT1080 cells were treated with 3 µM AGI-5198 twice every day for 5 days, followed by determination of relative 2HG 7 levels. Asterisk denotes a statistical difference between AGI-5198 and DMSO-treated cells, twosided t-test P < 0.001 (graph represents 3 independent experiments). Error bars represent standard deviation. (h) αKG abundance in NHA expressing empty vector control, IDH1
WT or IDH1 R132H . Asterisk denotes a statistical difference between IDH1 R132H and empty vector control cells, twosided t-test P = 0.04 (graph represents 3 independent experiments). Error bars represent standard deviation. (i) Decreased DEPTOR levels in NHA treated with 1 mM 2HG during 8 hours. 8 Supplementary Figure 6 . Frequent genomic loss and decreased mRNA levels of KDM4A in various types of cancer. (a-i) Analysis of mRNA expression levels and gene copy number of KDM4A in breast invasive carcinoma (a), head and neck squamous cell carcinoma (b), kidney chromophobe (c), kidney renal clear cell carcinoma (d), liver hepatocellular carcinoma (e), lung adenocarcinoma (f), lung squamous cell carcinoma (g), ovarian serous cystadenocarcinoma (h) and skin cutaneous melanoma (i). (j) Loss (GISTIC annotation -2 and -1), normal (GISTIC annotation 0) and gain (GISTIC annotation +1 and +2) of copy number of KDM4A gene in 2812 cancer samples from TCGA and analysed with cBioPortal for Cancer Genomics 1, 2 .
